Industry News and Notes – October 2011
Published in Biolines October 2011
Christie Administration Announced Funding to Spur Small Business Lending and Job Creation in New Jersey
TRENTON — Governor Chris Christie on October 12 announced that the State of New Jersey has been approved by the U.S. Department of Treasury for $33.8 million in funding through the State Small Business Credit Initiative (SSBCI), part of the federal Small Business Jobs Act of 2010, to encourage small business lending and job creation in the state. The intent of the SSBCI, which is to create jobs and strengthen state lending programs, mirrors New Jersey’s recent efforts to enhance its support of the state’s small business community.
Click here to learn more.
BIO Applauds the Intent to Create a National Bioeconomy Blueprint
WASHINGTON, DC — Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood on October 13 released the following statement on the Obama Administration’s intent to create a National Bioeconomy Blueprint:
“BIO is extremely pleased that President Obama has committed to create a National Bioeconomy Blueprint to leverage the U.S. biotechnology industry to spur growth in our nation’s economy. The biotech sector directly employs 1.42 million workers and supports an additional 6.6 million jobs nationwide. With the Administration’s support, the biotech sector can expand its role as an economic engine for growth – creating high-wage, high-skilled jobs that offer the most promise to cure disease, feed the hungry, clean our environment and provide renewable sources of energy.”
Click here to read more.
News from Our Colleges and Universities
Rutgers to Hold Drug Discovery and Development Day on November 3
Drug Discovery and Development Day, sponsored by the Office of the Vice President for Research and Economic Development, will highlight Rutgers faculty and centers conducting research on aspects of the drug discovery and development process.
The event will be held November 3, from 9:30 a.m. to 4:30 p.m. at the Heldrich Center, 10 Livingston Ave., New Brunswick.
Along with guest speakers from the pharmaceutical industry, Rutgers faculty will present research leading to cutting-edge discoveries in fields ranging from antibiotics for drug-resistant infections to cancer.
- Eddy Arnold, Rutgers Board of Governors Professor of Chemistry and Chemical Biology, will discuss his experiences with the development of the new AIDS drug, Edurant (rilpivirine). Arnold led the Rutgers team that collaborated with researchers at Johnson & Johnson subsidiary Janssen Pharmaceutica in developing the drug.
- Bob Zivin, Senior Director of J&J’s Corporate Office of Science and Technology, will moderate a panel composed of J&J colleagues Andrea Kamage and Paul Burnett, on “Avoiding Pitfalls on the Road to Translation: Stories from the Trenches.”
This event is free of charge. A complimentary buffet lunch will be served. Discounted parking on site will be available.
Rutgers-Affiliated Startup Gets Funding for Breast Cancer Analysis Tools
By applying technology originally developed to determine how aggressive prostate cancer is when present in a person, Anant Madabhushi is now developing a tool to speed up and lower the cost to predict how aggressive a common form of breast cancer is likely to be, according to NJBIZ.
Through his Piscataway company, Ibris Inc., the Rutgers University professor of biomedical engineering is in the process of licensing the imaging technology used to reveal difficult-to-identify characteristics. The National Institutes of Health announced Thursday that it has awarded Ibris more than $200,000 through the Small Business Innovation Research program to help Madabhushi establish how well his system predicts long-term patient outcomes.
Click here to learn more.